Details for Patent: 12,213,989
✉ Email this page to a colleague
Which drugs does patent 12,213,989 protect, and when does it expire?
Patent 12,213,989 protects LIVTENCITY and is included in one NDA.
This patent has twenty-one patent family members in nineteen countries.
Summary for Patent: 12,213,989
| Title: | Use of maribavir in treatment regimens |
| Abstract: | Characterization of drug-drug interaction properties and pharmacological properties of maribavir is useful to inform potential drug-drug interactions and dosing strategies when administering with co-medications. |
| Inventor(s): | Heng Song, Kefeng SUN, Matthew Crouthamel, Grace Chen, Andy Z. X. ZHU, Ingrid Nicolle Michon, Howard James Burt, Zoe Elizabeth Barter, Sibylle Neuhoff |
| Assignee: | Takeda Pharmaceutical Co Ltd , Takeda Pharmaceuticals USA Inc |
| Application Number: | US18/646,035 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 12,213,989
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | LIVTENCITY | maribavir | TABLET;ORAL | 215596-001 | Nov 23, 2021 | RX | Yes | Yes | 12,213,989 | ⤷ Start Trial | TREATING POST-TRANSPLANT CMV INFECTION/DISEASE REFRACTORY TO GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR OR FOSCARNET BY ADMINISTERING 1200 MG MARIBAVIR TWICE DAILY, WHERE THE PATIENT IS CONCOMITANTLY EXPOSED TO OR RECEIVING PHENYTOIN OR PHENOBARBITAL | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,213,989
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2022395001 | ⤷ Start Trial | |||
| Australia | 2025202348 | ⤷ Start Trial | |||
| Canada | 3237758 | ⤷ Start Trial | |||
| China | 118541156 | ⤷ Start Trial | |||
| Denmark | 4433065 | ⤷ Start Trial | |||
| European Patent Office | 4433065 | ⤷ Start Trial | |||
| European Patent Office | 4748448 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
